Note 8 - Segment Reporting - Reconciliation of Segment Operations (Details) - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
General and administrative		$ 1,153,032			$ 1,566,085			$ 4,764,617	$ 9,135,225
Other income		2,405			8,080			14,056	58,851
Realized and unrealized loss		(183)			(629)			(262)	(1,115)
Net loss		(3,799,240)	$ (4,674,901)	$ (3,964,601)	(4,315,987)	$ (6,495,846)	$ (5,968,869)	(12,438,742)	(16,780,702)
Operating Segments [Member]
Revenues		0			0			0	0
Clinical and regulatory		1,680,061			1,740,207			5,046,279	5,845,783
Manufacturing		188,532			589,548			1,144,195	1,109,388
Research		313,323			240,701			950,640	236,855
General and administrative		1,144,444			1,331,484			4,192,630	6,605,217
Non-cash expenses(1)	[1],[2]	19,553			421,498			663,243	3,041,195
Other income		2,405			8,080			14,056	58,851
Other financing costs		(455,549)			0			(455,549)	0
Realized and unrealized loss		(183)			(629)			(262)	(1,115)
Net loss		$ 3,799,240			$ 4,315,987			$ 12,438,742	$ 16,780,702

[1] Includes $19,553 and $420,226 of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence

[2] Includes $19,553 and $420,226 of stock-based compensation expense for the three months ended September 30, 2025 and 2024, respectively, and $0 and $1,272 of depreciation and amortization expense for the three months ended September 30, 2025 and 2024, respectively. Includes $663,243 and $3,034,966 of stock-based compensation expense for the nine months ended September 30, 2025 and 2024, respectively, and $0 and $6,230 of depreciation and amortization expense for the nine months ended September 30, 2025 and 2024, respectively, inclusive of the amount stated in the preceding sentence.